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In vivo chemical screening is a broadly applicable approach not only for dissecting genetic pathways governing hematopoiesis
and hematological diseases, but also for ﬁnding critical components in those pathways that may be pharmacologically modulated.
Both high-throughput chemical screening and facile detection of blood-cell-related phenotypes are feasible in embryonic/larval
zebraﬁsh. Two recent studies utilizing phenotypic chemical screens in zebraﬁsh have identiﬁed several compounds that promote
hematopoietic stem cell formation and reverse the hematopoietic phenotypes of a leukemia oncogene, respectively. These studies
illustrate eﬃcient drug discovery processes in zebraﬁsh and reveal novel biological roles of prostaglandin E2 in hematopoietic and
leukemia stem cells. Furthermore, the compounds discovered in zebraﬁsh screens have become promising therapeutic candidates
against leukemia and included in a clinical trial for enhancing hematopoietic stem cells during hematopoietic cell transplantation.
1.Introduction
Zebraﬁsh has been used eﬀectively as a vertebrate model for
studying blood cell development and function (for reviews
see [1–5]). It is an advantageous model because the optical
clarity of its embryos, and their ex utero development
enables easy and real-time detection of hematopoietic cells
during development. A wide variety of tools and reagents
have been developed for in vivo labeling and imaging of
blood cells and for investigating blood cell function (for
reviews of these methods and protocols, see [6–10]). In
addition, transient and stable genetic manipulation can link
hematopoietic genes to their functions [11–16]. Added to
this arsenal of research tools available in zebraﬁsh is in vivo
chemical screening [17–20]. By exposing zebraﬁsh embryos
to a chemical library, bioactive compounds that aﬀect any
complex developmental and physiological processes may be
identiﬁed. Furthermore, in vivo chemical screening may be
used for uncovering chemical agents that modify a disease
phenotype in a whole animal. The compounds that induce
a unique biological eﬀe c tm a ys e r v ea si n v a l u a b l ep r o b e s
for identifying critical components of biological pathways,
and compounds that can reverse a disease phenotype in vivo
may have therapeutic potential or shed light on an eﬀective
therapeutic target. This innovative approach has created a
unique utility for the zebraﬁsh model in chemical biology
and contributed to its emerging role in drug discovery (for
additional reviews see [21–24]).
2. LinkingGenesto Their Functions: In Vivo
Chemical Screens versus Genetic Screens
Both genetic and in vivo chemical screens may be used to
dissect genetic pathways that regulate speciﬁc biological pro-
cesses. However, an in vivo chemical screen oﬀers the advan-
tageoftemporalcontrolthatatraditionalgeneticscreendoes
not. In a genetic screen, gene function is aﬀected from con-
ception. Thus, the role of a gene in early embryonic develop-
ment may preclude characterization of its roles during later
stages. On the other hand, in a chemical screen, compounds
that aﬀect the function of a gene can be administered at spe-
ciﬁc time points and for ﬁxed durations chosen by the inves-
tigator so that its roles at diﬀerent developmental stages may2 Advances in Hematology
be distinctly determined. In addition, in a genetic screen,
the roles of a protein family may sometimes be masked
by functional redundancy of its family members. However,
chemical modulators may exhibit similar activities against
multiple members of a protein family and can, therefore,
reveal their in vivo cumulative roles. It should be noted that
some compounds may aﬀect multiple cellular proteins and
thus their on-target eﬀects should be carefully veriﬁed using
additional chemical agents as well as genetic manipulations.
Taken together, in vivo chemical screens may complement
traditional genetic approaches and uncover hematopoietic
genes that cannot be identiﬁed in genetic screens.
3. Drug Discovery: In Vivo
Phenotype-Based Chemical Screening versus
Target-BasedApproach
Currently, the most common approach for identifying po-
tentialtherapeuticsisthetarget-drivenapproach(forreviews
see [25, 26]). This approach relies on ap r i o r iunderstanding
of disease mechanisms to the point of knowing a speciﬁc cel-
lular component to be targeted. Thereafter, lead compounds
may be obtained using in vitro or cell-based assays to deter-
mine binding to or modulation of target activity. Typically,
these leads will be further optimized using these assays again
before being assessed for their in vivo eﬃcacy and toxicity.
Targets employed by this approach are often enzymes such as
kinasesthatarelikelytohavesmall-moleculebindingpockets
(for more discussions on target druggability, see reviews
[26, 27]). Proteins that do not have an obvious pocket, such
as transcription factors that often act by recruiting other
cofactors, are sometimes dubbed undruggable targets.
Target-based chemical screens performed in vitro or in
cultured cells are usually very eﬃc i e n ta n da r ea b l et os a m p l e
through tens of thousands of compounds. Even so, many
drug candidates so identiﬁed fail because of poor in vivo
potency, intolerable side eﬀects, or inability to demonstrate
clinical eﬃcacy (for reviews see [28, 29]). In comparison,
chemical screens performed in a whole organism may
identify working drugs with a higher rate of success since
in vivo potency and toxicity are evaluated simultaneously
during the primary screen [30]. Moreover, by design these
screens directly identify compounds that have demonstrated
their eﬀectiveness of reversing a disease phenotype in vivo.
Instead of examining one target as in the target-driven ap-
proach, in vivo screening is able to interrogate any potential
therapeutic targets existing in a biological system that may
mediate a disease phenotype, including targets that act in a
non-cell-autonomous manner. In many circumstances, the
mechanisms of disease pathology are not fully understood,
so a target-driven approach is lacking. In vivo chemical
screening, on the contrary, can be performed before a valid
molecular target is identiﬁed.
Although in vivo screening has a demonstratedly good
likelihoodofﬁndingeﬃcaciousdrugcandidates,ﬁguringout
theirmodeofactioncanbeachallenge.Asigniﬁcantamount
of eﬀort is usually needed to identify the molecular target
of the candidate compound. Nevertheless, due to several
important advances in analytical research tools including
mass spectrometry, proteomics, genomics, metabolomics,
expressional proﬁling, and chemical informatics as well as
novel in vivo labeling methods, the eﬃciency and success
rate of target identiﬁcation have improved signiﬁcantly in
recent years [31–34].Inaddition,invivochemicalscreensare
sometimes performed using chemical libraries consisting of
known bioactive compounds, so that the signaling pathways
mediating a disease phenotype can be uncovered relatively
quickly once chemical suppressors of the phenotype are
identiﬁed.
4. EfﬁcientIn Vivo Chemical
Screeningin Zebraﬁsh
Some of the model organisms that may be used for in vivo
chemical screening are Drosophila, C. elegans and embry-
o n i c / l a r v a lz e b r a ﬁ s h( Danio rerio)( f o rar e v i e ws e e[ 35]).
All of these models have the scalability required for high-
throughput screening. Among them, zebraﬁsh is the only
vertebrate model and thus possesses the closest physiological
similarities to humans.
Featuresofzebraﬁshthatenableeﬃcientinvivochemical
screening are multiple. First is their fecundity. One pair of
zebraﬁsh can produce 100–200 embryos each week, so even
a medium size aquarium with a couple hundred ﬁsh can
producethousandstotensofthousandsofembryosperweek
forscreening.Second,zebraﬁshembryosaresmall.Generally
3–5 embryos can be arrayed in a well of a 96-well plate
containing 100–200μL of ﬁsh water. Further, most cell-
permeable small molecules (with octanol:water partition
values, or logP, above zero) can penetrate zebraﬁsh embryos
even when they are inside the chorions [36]. Thus, com-
pounds can be added directly into the water surrounding the
embryos. For screens performed in 96-well plates at a 10-
μM concentration, only 1-2 micrograms of each compound
will be needed for screening. In addition, zebraﬁsh develop
quickly, embryos/larvae at 1–5 days after fertilization (dpf)
alreadypossessvarious functionalphysiologicalsystems.The
short developmental timeframe signiﬁcantly condenses the
time needed for experimentation. Figure 1 shows a schema
of in vivo chemical screening in zebraﬁsh.
The assays employed for in vivo screening will depend
on the phenotype of interest. For example, transgenic lines
expressing ﬂuorescent proteins under the control of cell-
type-speciﬁc promoters may be used to track the production
or location of speciﬁc cell types. Thus, zebraﬁsh pu.1, gata1,
mpo, lyzC, csf1r, rag2, lck, CD41, or scl reporter lines among
others may be used to identify chemical modulators of
myeloid cells, erythrocytes, neutrophils, macrophages, T
cells, thrombocytes, or hemangioblasts, respectively [37–45].
Whole-mount immunostaining and RNA in situ hybridiza-
tion may also be used to detect cell proliferation or expres-
sion of cell diﬀerentiation markers. Even a wide range of
physiological outputs and responses may be used as screen-
ing readouts, such as chemical-induced enterocolitis, injury-
induced inﬂammation, host-pathogen interactions, and
laser-induced thrombosis [46–52]. Some of these assays mayAdvances in Hematology 3
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Figure 1: Chemical screening using zebraﬁsh embryos. Step 1—Wild-type, reporter, or mutant zebraﬁsh are crossed to obtain embryos.
Step 2—Once reaching an investigator-speciﬁed developmental stage (usually between 0–5 days after fertilization), embryos are arrayed into
multi-well plates either manually or by automation. Step 3—Compounds from a chemical library are added into the wells containing the
embryos using a multichannel pipette or a pin-transfer device. Step 4—After reaching the developmental stage for phenotype manifestation,
which is usually within hours to a couple of days after the compound treatment, embryos may be subjected to staining procedures, reporter,
or functional assays to detect chemical-induced phenotypes or reversal of genetic phenotypes. The images shown here depict diﬀerential
hematopoietic gene expression between the compound-treated (red circle) and vehicle-treated (black circle) embryos as detected by RNA in
situ hybridization. Step 5—In vivo phenotypes can be detected by visual inspection or by automated imaging and recording. Thus, the whole
screening procedure, once optimized, may be automated for high-throughput experimentation and ﬁnished within a few days. In addition,
a wide range of phenotypes may be detected in vivo.
be processed by automated liquid handling machines or may
be recorded using automated imaging systems and analyzed
using customized software [51, 53–56]. Thus, conducting
chemical screening in zebraﬁsh provides great potential for
identifying modulators of hematopoiesis and hematological
diseases.
5. Considerations for ScreeningDesigns,
HitEvaluation,and Translationto Humans
5.1. Screening Designs. As in any other types of chemi-
cal screens, the quality of the hits obtained in zebraﬁsh
screens can be directly inﬂuenced by the screening designs.4 Advances in Hematology
For example, if a screen is based on the reduction of the
signals in a reporter assay, it may be prone to identifying false
positivessuchastoxiccompounds.Inthiscase,aquickvisual
scanofembryo/larvaviabilitybeforeconductingthereporter
assay may help exclude those nonspeciﬁc hits. In addition,
since proper embryonic development depends on precise
execution of multiple sequential processes, compounds
added at diﬀerent times will have the opportunity to aﬀect
diﬀerentdevelopmentalsteps.Thus,thetiming andduration
of chemical treatment are also likely to aﬀect the screening
outcomes. If a screen utilizes a transgenic line, additional
validation steps should be incorporated to examine whether
the hit compounds may aﬀect the promoter used for driving
the transgene or the stability of the transgene itself. For
example, in one of the screens that we have performed,
we have identiﬁed several hits that suppress the heat shock
promoter used for driving the expression of an oncogene
rather than the activity of the oncogene [20]. Whenever
possible, positive controls should be used to validate that
zebraﬁsh models exhibit similar molecular machineries and
pharmacological responses as humans do (if the screening
purpose is drug discovery) for the biological processes under
investigation. This conﬁrmation beforehand will facilitate
the likelihood of relevantly translating the ﬁndings from
zebraﬁsh screens to human conditions.
In addition, it is important to conduct a pilot screen
using 100∼300 compounds and one screening plate of
untreated embryos/larvae to evaluate the robustness and
potential variables of the screening methods, including the
degrees of natural variations among diﬀerent clutches of
embryos/larvae. A pilot screen may also provide information
as regard to the potential hit rates. On one hand, in vivo
screening methods may cast a broad net for identifying com-
pounds that elicit the phenotype-of-interest through various
mechanisms. On the other hand, if the hit rates are higher
than 1-2%, researchers may wish to incorporate secondary
screening strategies or consider a diﬀerent screening method
in order to limit the hits to the ones that are likely to
be of potential interest to the investigators. For example,
we previously showed that immediately after the expression
of the leukemia oncogene AML1-ETO, gata1 expression
is abolished, whereas myeloperoxidase (mpo) expression is
increased at a later time point [57]. We conducted a chemical
suppressorscreenandidentiﬁedvariouscompoundsthatcan
restore gata1 expression in the presence of AML1-ETO [20].
We have also veriﬁed the therapeutic potential of some of
the hits identiﬁed in this screen, and these results will be
discussed in more detail later. Conceivably, a chemical sup-
pressor screen can also be performed based on the reversal
of mpo upregulation in the same zebraﬁsh model. The latter
screening strategy may not only identify compounds that
directly antagonize AML1-ETO’s eﬀects but also additional
compounds that suppress the accumulation of mpo+ cells
through AML1-ETO-unrelated mechanisms. The choices of
screeningdesignsaresubjecttoeachinvestigator’sdiscretion.
5.2. Hit Evaluation and Translation to Humans. The potency,
eﬀectiveness, and speciﬁcity of the conﬁrmed hits obtained
from zebraﬁsh screens have already been demonstrated in
vivo. Thus, these hits have a high probability of being
eﬀective in other in vivo systems. Both hematopoietic and
other nonhematopoietic eﬀects of these candidate com-
pounds should be evaluated further in embryonic/larval
zebraﬁsh. The eﬀects of the candidate compounds on cell
diﬀerentiation, proliferation, or survival can be evaluated
usingwhole-mountRNAinsituhybridization,whole-mount
immunostaining or staining with lineage-speciﬁc cytological
dyes such as Sudan Black for neutrophils and o-dianisidine
for hemoglobin. These in vivo eﬀects may be assessed facilely
using embryonic/larval zebraﬁsh. For example, we have
found that AML1-ETO can reprogram hematopoietic cell
fate decisions, converting the erythroid cell fate to the granu-
locytic cell fate. We have also found that nimesulide, a chem-
ical suppressor of AML1-ETO, can reverse these eﬀects in
zebraﬁsh. AML1-ETO has been shown to suppress erythroid
diﬀerentiation in mammalian cells, and we have conﬁrmed
that nimesulide can also reverse AML1-ETO’s eﬀects in
cultured cells [20]. The eﬀects of candidate compounds on
leukocyte or thrombocyte function can also be assessed in
embryonic/larval zebraﬁsh using an injury model for neu-
trophil chemotaxis, a bacterial infection model for phago-
cytosis, or a laser-induced coagulation assay [47, 58, 59].
Moreover,lineage-speciﬁchematopoieticcellscanbeisolated
from control and compound-treated embryos/larvae of
various ﬂuorescent reporter lines mentioned earlier by ﬂow
cytometryfortranscriptionalproﬁlinganalysis.Interestingly,
thenonhematopoietic eﬀectsmaysometimesprovideinstru-
mental information as to the mechanisms of action of the
candidate compounds. For example, a candidate compound
may cause a developmental phenotype similar to the pheno-
type caused by other genetic mutations or other chemicals
with known bioactivities, suggesting that the candidate
compound acts through a similar pathway as these other
modulations do. The eﬀects of the candidate compounds
can also be evaluated in adult zebraﬁsh using standard
hematopoietic assays adapted from mouse models, including
irradiation followed by hematopoietic cell transplantation
a n di r r a d i a t i o nr e c o v e r ya s s a y s ,a sw e l la sl e u k e m i cc e l l
xenograft and limiting dilution transplantation [37, 60–64].
Thezebraﬁshprovidestheinvestigatortheﬂexibilityatwhich
point to verify the eﬀects of these compounds in mammalian
systems. While the degree of conservation between zebraﬁsh
andmammalsinhematopoiesisandinthefunctionsofmany
hematopoietic cell lineages is high, conservation of humoral
regulators and the adaptive immune system is presently
less clear. However, rapid advancement in those areas is
anticipated. For those biological processes already shown to
be highly conserved, the translatability of the screening hits
from zebraﬁsh to humans will likely to be high.
6. Zebraﬁsh Hematopoiesis and Hematological
DiseaseModels inZebraﬁsh
6.1. Hematopoiesis. Zebraﬁsh possesses a similar set of blood
lineages as the mammals [11, 14, 63, 65–71]. The genes
involved in blood cell development are also highly conservedAdvances in Hematology 5
between zebraﬁsh and mammals [72, 73]. Thus, it is a suit-
able model for investigating the genetic pathways regulating
hematopoiesis and hematological diseases.
As in mammals, during embryonic development, zebra-
ﬁsh ﬁrst exhibit a primitive wave of hematopoiesis and later
produce several intermediate cell types that eventually con-
tributetodeﬁnitivehematopoiesis(formoredetailedreviews
see [74, 75]). During primitive hematopoiesis, which begins
around 11 hours after fertilization (hpf), zebraﬁsh embryos
produce myeloid and erythroid cells in two anatomically
separate locations. Myeloid cells, which express the tran-
scription factor pu.1, are formed in the anterior lateral plate
mesoderm (ALM), while erythroid progenitors expressing
the gata1 transcription factor are formed in the posterior
lateral plate mesoderm (PLM). It has been shown that
hematopoietic cell fate in both blood islands is determined
by the expression of these two genes. While knockdown of
pu.1induces erythropoiesis in the ALM,knockdown of gata1
promotes myelopoiesis in the PLM [76, 77]. These results
indicate that primitive hematopoiesis in embryonic zebraﬁsh
produces bi-potent hematopoietic progenitor cells. Thus,
these two synchronously speciﬁed blood populations may be
useful for identifying important genes that regulate myeloid
and erythroid cell fate determination. In a later section of
this paper, we will discuss a study that utilizes these cells to
uncoversomeoftheAML1-ETO’soncogeniceﬀectsthatlead
to acute myeloid leukemia [20, 57].
In zebraﬁsh, multipotent hematopoietic stem cells
(HSCs)originateinthehemogenicendotheliumoftheaorta,
which is equivalent to the aorta-gonad-mesonephros (AGM)
in mammals [78]. Using in vivo lineage-tracing experiments,
it has been shown that these newly emerged HSCs will
subsequently colonize a transient hematopoietic tissue called
the caudal hematopoietic tissue (CHT), which may be com-
parable to another mammalian embryonic hematopoietic
site in the fetal liver [79–81]. Finally, HSCs from those
regions will migrate to and seed both kidney (equivalent to
bone marrow in mammals) and thymus, the ﬁnal hemato-
poietic organs that remain through adult life [79–81]. As
in mammals, zebraﬁsh HSCs express runx1 and cmyb,a n d
runx1 deﬁciency abrogates deﬁnitive hematopoiesis in ﬁsh
[78, 82–84]. Several major signaling pathways that regulate
HSC formation and homeostasis in mouse models also aﬀect
HSC formation in zebraﬁsh, such as the Hedgehog (Hh)
pathway and the Notch-Runx pathway [78, 85]. Recently, an
in vivo chemical screen in zebraﬁsh has identiﬁed important
roles of the prostaglandin-E2-(PGE2-) Wnt signaling path-
way in HSC formation [19, 86], which will be discussed in
more detail later. These ﬁndings suggest that zebraﬁsh and
mammals utilize similar genetic circuitry for regulating HSC
formation.
6.2. Hematological Disease Models. Due to the easiness of
inspecting blood cell phenotypes in zebraﬁsh embryos, a
large number of blood mutants have been isolated in three
large-scale genetic screens [11, 14, 87, 88]. Many of these
blood mutants have defects in the maturation or iron
transport of erythrocytes, and their related phenotypes and
orthologous gene mutations have been deﬁned in humans
[89–91]. Transgenesis approaches have also been used to
create various hematological disease models in zebraﬁsh, of
which the majority are blood cancer models [20, 38, 57, 92–
96]. In these studies, ectopic expression of human oncogenes
resulted in zebraﬁsh phenotypes reminiscent of human
leukemia characteristics. In addition, investigators can now
perform eﬃcient targeted gene disruption in zebraﬁsh using
engineered zinc ﬁnger nucleases (ZFNs) and transcription
activator-like eﬀector (TALE) nucleases [13, 16, 97–100]. In
the future, many of these hematological disease models may
be used for chemical suppressor screens. The vast array of
researchtoolsavailableinthezebraﬁshmodelcombinedwith
in vivo chemical screening will prove useful in providing
novel insights into the molecular mechanisms and potential
therapy for hematological diseases.
7.In Vivo Identiﬁcation of Hematopoietic
Stem Cell(HSC)Chemical Modulators
Compounds that can augment HSC formation and func-
tion may exert therapeutic beneﬁts to patients undergoing
hematopoietic cell transplantation. North et al. performed a
chemical screen to identify small molecules regulating HSC
formation in zebraﬁsh embryos [19]. In this study, embryos
were exposed between 11 and 36hpf to 2,357 compounds
from three chemical libraries of known bioactive com-
pounds. As mentioned above, HSCs are cmyb+ and runx1+
and both transcription factors are indispensable for HSC
development. By examining cmyb and runx1 expression
using RNA in situ hybridization, the authors found 35 com-
pounds that increased HSC numbers and another 47 com-
poundsthatdecreasedthem.Basedontheirknownbioactivi-
ties,theyfoundthat10ofthesecompoundsaﬀectprostanoid
biosynthesis. Prostanoids, including prostaglandins, prosta-
cyclins, and thromboxanes, are lipid mediators that play
major roles in inﬂammation and other physiological re-
sponses. The cyclooxygenases (COXs), including COX-1 and
COX-2 (also known as prostaglandin G/H synthase 1 and
2), convert arachidonic acid into prostaglandin H2, which
canthenbemetabolizedintootherprostanoidsbyadditional
enzymes [101]. Interestingly, the authors found that while
exposure to COX inhibitors such as celecoxib and sulindac
reduced cmyb/runx1 expression in the hemogenic aorta,
exposure to linoleic acid, a precursor of arachidonic acid,
enhancedit.Previouslyithadbeenshownthatprostaglandin
E2 (PGE2) is the major prostanoid produced in zebraﬁsh
embryos[102].Thus,Northetal.conﬁrmedtheinvolvement
of the prostaglandin pathway in HSC formation by incubat-
ing zebraﬁsh embryos with PGE2 or selective inhibitors of
COX-1 and COX-2, as well as by genetic knockdown of ptgs1
and ptgs2 that encode COX-1 and COX-2 proteins, respec-
tively. Subsequently, the authors investigated the expression
patterns of ptgs1 and ptgs2 and found that both genes were
upregulated at the onset of deﬁnitive hematopoiesis. While
both genes were expressed in the HSCs, ptgs1 was also
expressed in the neighboring endothelium. These results
strongly suggest that COX-1 and COX-2 promote HSC
formation through functions in both the HSCs and their6 Advances in Hematology
niche. Furthermore, Goessling et al. showed that PGE2
promotes HSC formation by activating the Wnt/β-catenin
signaling pathway [86].
In their screen, North et al. also found 22 compounds
that might regulate HSC formation through their eﬀects on
bloodﬂow,suchascompoundsaﬀectingα-andβ-adrenergic
receptors, Ca2+ or Na+/K+ channels, nitric oxide (NO) syn-
thesis, or the angiotensin pathway [103]. They showed that
blood ﬂow had a positive impact on cmyb/runx1 expression,
suggesting that the hemodynamic force on the endothelium
might be an inducing factor for the emergence of HSCs. In
addition, the authors found that NO donors could stimulate
HSC formation even in the silent heart mutant, which
does not exhibit blood ﬂow. Using mosaic transplantation
experiments, they discovered that NO positively regulated
HSC through cell-autonomous signaling.
8. Validation of HSC Chemical Modulators and
Their ClinicalPotential
Hematopoietic cell transplantation (HCT) is frequently used
in the treatment of hematological malignancies. HSCs not
onlyself-renewbutalsogiverisetoallbloodlineagesandcan
repopulate an entire hematopoietic system. Patients about
to receive HCT need to undergo myeloablation and are
treated simultaneously with immunosuppressants to prevent
transplant rejection. It is essential that the transplanted
HSCs eﬀectively and eﬃciently engraft in the bone marrow.
Various methods aiming to enhance the in vitro and in
vivo expansion of stem/progenitor cells and their homing
eﬃciency to bone marrow are currently under intensive
investigation [104–107]. The chemical modulators of HSCs
identiﬁed by North et al. in zebraﬁsh represent another new
therapeutic opportunity.
Northetal.showedthatexvivoexposureofmousewhole
bone marrow (WBM) or puriﬁed lin−Sca1+c-Kit+ (LSK)
cells to dimethyl-prostaglandin E2 (dmPGE2), a long-lasting
derivative of PGE2, signiﬁcantly increased the progenitor cell
numbers as measured by spleen colony-forming units at day
12 after transplantation (CFU-S12) in the recipient mice.
Using a limiting dilution competitive repopulation analysis,
they found that dmPGE2-treated WBM resulted in 4- and
2.3-fold increases of HSCs in the recipients compared to the
untreated cells at 12 and 24 weeks, respectively, following
the transplants [19]. To deﬁne the mechanisms of action of
PGE2, Hoggatt et al. showed that ex vivo exposure to PGE2
promotedHSChomingeﬃciency,proliferation,andsurvival
during engraftment [108].
Clinically, sources for HCT include bone marrow, mobi-
lized peripheral blood stem cells (MPBSCs), or human cord
blood (hCB). Approximately 20% of HCTs in the United
States are conducted using hCB [109]. However, recovery
after hCB transplant often takes a very long time due to the
limited volume of its source. Thus, Goessling et al. went on
to show that dmPGE2 could enhance hCB hematopoietic
colony formation in vitro and its engraftment in xeno-
transplantation [110]. Interestingly, the authors found that
hCB samples treated with dmPGE2 exhibited gene expres-
sion patterns reminiscent of the HSCs emerged from a
vascular niche [110]. Since hCB contains both HSCs and
endothelial cells, the authors postulated that dmPGE2 might
promote HSC formation from hemogenic endothelial cells,
analogous to the scenario in developing zebraﬁsh embryos.
Alternatively, Butler et al. have shown that endothelial cells
can provide signals for retaining HSC multipotency [111].
Finally, Goessling et al. provided evidence demonstrating
preclinical safety of their regimen in nonhuman primate
autologous transplantation [110]. Thus, from its initial
discovery using an in vivo chemical screen in zebraﬁsh, PGE2
is now entering a Phase I clinical trial.
9.In Vivo Identiﬁcation of Acute Myelogenous
Leukemia (AML) Chemical Suppressors
9.1.AML1-ETOandthet(8;21)AML. Ourlabhasconducted
an in vivo chemical screen to identify compounds that could
reverse the hematopoietic phenotypes of a human leukemia
oncogene [20]. AML1-ETO is a fusion gene resulting from
t(8;21)(q21;q22) chromosomal translocation, and it is one
of the most common translocation products in AML. In
particular, AML1-ETO expression accounts for 40% of AML
in the FAB (French-American-British) M2 subtype [112].
These patients can be characterized by overabundance of
granulocytic blast cells.
AML-1, also known as Runx-1, is one of two subunits
thatformaheterodimerictranscriptionfactorcalledthecore
binding factor (CBF). The CBF plays many important roles
in hematopoiesis by regulating hematopoietic gene expres-
sion (for review see [113]). It has been shown that AML1-
ETO exerts a dominant-negative eﬀect on CBF function;
however, recent studies also suggest that it produces other
gain-of-function eﬀects that account for its oncogenicity
[114]. Expression of AML1-ETO enhances HSC expansion
both in vitro and in vivo and promotes myelopoiesis while
blocking myeloid maturation [115–119]. Despite intensive
studiesongeneregulationmediatedbyAML-ETO,todateno
eﬀective therapeutic target has been validated in vivo.T h u s ,
we postulated that a phenotype-based, nonbiased approach
such as in vivo chemical screening might uncover potential
therapeutics and identify the critical downstream eﬀectors of
AML-ETO.
9.2. A Zebraﬁsh Model for AML1-ETO Leukemia. At r a n s -
genic zebraﬁsh line Tg(hsp:AML1-ETO) was established to
enableheat-inducibleexpressionofhumanAML1-ETO[57].
It was found that expression of AML1-ETO in embryonic
zebraﬁsh resulted in an accumulation of hematopoietic cells
intheposteriorbloodisland[57,120].Cytologicalanalysisof
the hematopoietic cells isolated from the transgenic embryos
showed plentiful immature cells seldom seen in the control
samples. In addition, genome-wide expression analysis iden-
tiﬁed various important similarities between the hematopoi-
etic cells of the transgenic zebraﬁsh and human t(8;21)
leukemiacells[57].PreviouslyithadbeenshownthatAML1-
ETO suppresses erythroid diﬀerentiation in human multipo-
tent hematopoietic cells [121]. In the zebraﬁsh model, it was
found that AML1-ETO caused the downregulation of gata1Advances in Hematology 7
and the upregulation of pu.1 in multipotent hematopoi-
etic progenitors, suggesting a conversion of erythroid to
myeloid cell fate. Moreover, the accumulated hematopoietic
cells strongly expressed the myeloperoxidase (mpo)g e n e ,
indicative of a granulocytic cell fate. A previous study had
shown that AML1-ETO downregulates c/ebpα, resulting in a
maturation block of the granulocytic cells in human t(8;21)
AML [122]. In the zebraﬁsh model, we also observed a
dramaticreductionofc/ebpαexpression,suggestingthatonly
two days after its expression in zebraﬁsh embryos, AML1-
ETO induced an accumulation of granulocytic blast cells
resembling the clinical features of human t(8;21) AML.
9.3. Chemical Screening in the Zebraﬁsh Model of AML-ETO.
A library of 2,000 bioactive compounds was screened using
the Tg(hsp:AML1-ETO) zebraﬁsh model [20]. The screening
compounds were added to embryos at 12–16 hpf, followed
by 1 hour of heat treatment to induce AML1-ETO expres-
sion. Fifteen hit compounds were identiﬁed by restored
gata1 expression in the transgenic embryos as measured
by RNA in situ hybridization. We found that some of the
compounds aﬀected the heat shock response in zebraﬁsh,
preventingAML1-ETOexpression.Inaddition,weidentiﬁed
a histone deacetylase (HDAC) inhibitor sodium valproate as
a chemical suppressor of AML1-ETO’s eﬀects. HDAC is a
transcription corepressor that is known to interact with the
ETO moiety of the AML1-ETO protein [123]. It has been
shownthatrecruitmentofHDACiscriticalforAE’sfunction,
and that an HDAC inhibitor trichostatin A (TSA) induces
diﬀerentiation and apoptosis of a t(8;21) AML cell line
[124]. We have shown previously that TSA also reversed the
hematopoietic phenotype of Tg(hsp:AML1-ETO)z e b r a ﬁ s h
[57]; therefore, the discovery of sodium valproate validated
the biological relevance of the chemical screen performed on
the AML1-ETO zebraﬁsh model.
Interestingly, nimesulide, a selective COX-2 inhibitor,
was also identiﬁed in this screen [20]. Subsequently, we
showed that treatments with indomethacin (a nonselective
COX inhibitor), NS-398 (a selective COX-2 inhibitor), and
nimesulidenotonlyrestoredgata1expressionbutalsoinhib-
ited increased expression of mpo in the transgenic embryos.
Furthermore, we demonstrated that these drugs’ eﬀects were
on target because they could be reversed by supplementing
a downstream metabolite PGE2. Thus, the hematopoietic
diﬀerentiation defects induced by AML1-ETO in vivo can be
rescued by inhibiting the COX enzymes.
10. Validation of AML Chemical Suppressors
andTheir ClinicalPotential
Since COX inhibitors scored as hits in our screen, we investi-
gatedthegenescodingforCOXproteinsandfoundthatptgs2
but not ptgs1 expression was signiﬁcantly upregulated in the
hematopoietic cells of Tg(hsp:AML1-ETO)z e b r a ﬁ s h[ 20].
At the time of this discovery, very little was known about
the potential contribution of the COX enzymes in AML
leukemogenesis, although overexpression of COX-2 had
beenreportedinvarioustypesofepithelialtumors,including
colorectal carcinoma and breast cancers [125, 126]. More-
over, PGE2 had been shown to promote colon cancer cell
growth via a β-catenin-dependent signaling pathway [127,
128]. As in zebraﬁsh, we found that AML1-ETO induced
ptgs2 but not ptgs1 expression in the K562 human myeloid
leukemia cell line [20]. AML1-ETO induced the activity of
a β-catenin reporter and inhibited erythroid diﬀerentiation
in these cells, and both eﬀects could be abrogated by NS-
398. Subsequently, we found that genetic knockdown of β-
catenin rescued AML1-ETO’s eﬀects in zebraﬁsh embryos
[20]. Thus, AML1-ETO aﬀects hematopoietic diﬀerentiation
through the COX-2/β-catenin pathway in both zebraﬁsh and
human leukemia cells.
Since the publication of these ﬁndings, we have obtained
strong evidence indicating that AML1-ETO also signals
through a COX-2/β-catenin pathway in mouse bone marrow
cells (Zhang et al., unpublished results). We have found
that COX inhibitors can eﬀectively suppress in vitro serial
replating of hematopoietic stem/progenitor cells expressing
AML1-ETO as well as AML1-ETO-mediated tumorigenesis
in various in vivo mouse models (Zhang et al., unpublished
results). Two recent studies have also explored the roles
of the COX enzymes and β-catenin in leukemia stem cells
expressing other leukemia oncogenes [129, 130]. In one of
the studies, Wang et al. showed that either the MLL-AF9
fusion oncoprotein or coexpression of Hoxa9 and Meis1a
could induce ptgs1 expression and β-catenin activation.
In addition, inhibiting COX activities using indomethacin
attenuated leukemia development induced by MLL-AF9 or
by coexpression of Hoxa9 and Meis1a oncogenes [129]. In
the other study, Steinert et al. found that a nonselective COX
inhibitor sulindac prevented β-catenin from being activated
and reduced in vivo growth of HSCs expressing PML/RARα
or PLZF/RARα oncogenes [130].
Collectively, these results suggest that inhibiting the
COX enzymes using nonsteroidal anti-inﬂammatory drugs
(NSAIDs) can suppress oncogenic function and β-catenin
activation in AML leukemia stem cells. Interestingly, case-
based studies have also suggested an inverse relationship
between NSAID usage and AML incidence [131, 132].
Although PGE2 can induce β-catenin expression and aug-
ment some aspects of HSC function as discussed above, it
has been shown that loss of β-catenin does not aﬀect normal
hematopoiesis in adult mice [133–136]. At present, a major
obstacle for achieving long-term survival of AML patients
is relapse. Although chemotherapy can eﬀectively induce
remission in the majority of patients, more than 50% of
the patients experience relapse within a year after remission
[137, 138]. In sum, these results suggest that NSAIDs may
impair leukemia stem cell function and thus their clinical
eﬃcacy in preventing AML relapse should be explored.
11. Final Considerations for
Drug Discovery in Zebraﬁsh
In this paper, we presented two speciﬁc studies on he-
matopoiesis that appropriately exemplify the general utility
of embryonic zebraﬁsh and phenotypic in vivo chemical8 Advances in Hematology
screening in discovering potential new therapeutics. In these
cases, the use of an in vivo screening platform allowed the
identiﬁcation of compounds that may act in a noncell auto-
nomous fashion such as hemodynamic forces, bypassed
the well-known technical diﬃculties involved in culturing
hematopoietic or leukemia stem cells, and also circumvented
the obstacles conferred by undruggable targets or unknown
disease mechanisms. Both of the studies uncovered novel
biological mechanisms as well as strong candidates for
clinical therapeutic use. It is important to note that most of
the advantageous features of the zebraﬁsh model occur at
its embryonic and larval stages. Thus, a disease phenotype
under investigation must manifest during these stages in
order to be most eﬀectively exploited for chemical screening.
Since multitudinous signaling pathways acting together in
zebraﬁsh during early development are also likely to play
important roles in maintaining homeostasis in adults and
may be disrupted or reactivated during disease progression,
a surrogate embryonic phenotype can often be very useful
for identifying potential disease modulators. For example,
compounds that suppress T-cell development in embryonic
zebraﬁsh may demonstrate potent inhibitory eﬀects against
T-cell leukemia [18]. Overall, drug discovery in zebraﬁsh
beneﬁts from the feasibility of high-throughput chemical
screening, closer physiological similarities to human than
invertebrate screening strategies, and the ability to create
complex disease models not achievable in vitro. The possibil-
ity of detecting a wider range of hematopoietic phenotypes
using innovative assays promises an ever-increasing role for
zebraﬁsh in future drug discovery processes.
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